Preechanukul Jay, Alrubayyi Aljawharah, Sun Bo, Arbe-Barnes Edward, Kokici Jonida, Gorou Frances, Prasitdumrong Sarun, da Costa Kelly A S, Fisher-Pearson Natasha, Hussain Noshin, Kucykowicz Stephanie, Ghosh Indrajit, Burns Fiona, Kinloch Sabine, Simoes Pedro, Bhagani Sanjay, Kennedy Patrick T F, Maini Mala K, Bashford-Rogers Rachael, Gill Upkar S, Peppa Dimitra
Division of Infection and Immunity, University College London, London, UK.
Nuffield Department of Clinical Neurosciences, University of Oxford, UK.
medRxiv. 2025 Apr 3:2025.03.30.25324898. doi: 10.1101/2025.03.30.25324898.
Chronic HBV infection disproportionately affects people living with HIV, who are often excluded from functional cure studies. This study investigates CD8 T cell profiles in HBV mono-infection versus HBV/HIV co-infection, examining the impact of long-term therapy on virus-specific responses with the goal of informing therapeutic strategies for immune restoration.
We analysed CD8 T cell responses in 61 participants (HBV n=20, HBV/HIV n=20, HIV n=21), on suppressive antiviral therapy. We assessed transcriptomic and proteomic profiles, focusing on exhaustion markers alongside virus-specific functional capabilities.
Transcriptomic analysis revealed a distinct signature in co-infection, with upregulation of genes associated with TCR signaling, inhibitory pathways and progenitor-exhausted markers (). This gene profile scored highly for a precursor exhausted (Tpex) CD8+ T cell signature, reflecting a "stemness" programme that maintains plasticity despite chronic antigen exposure. Proteomic analysis confirmed higher frequencies of precursor exhausted TCF-1CD127PD-1 CD8 T cells in co-infection, while HBV mono-infection showed predominance of terminally exhausted ToxTCF-1CD127 cells. These differences correlated with more robust, polyfunctional HBV-specific responses in co-infection against surface and core antigens. Lower HBsAg levels and longer treatment duration in co-infection associated positively with Tpex populations and functional responses and inversely with terminal exhaustion.
Our findings demonstrate that individuals with well-controlled HBV/HIV co-infection maintain more robust CD8 T cell responses with preserved stem-like properties supporting ongoing antiviral function. These results underscore the benefits of early antiretroviral intervention and the need for tailored immune-modulatory therapies to restore antiviral functionality in these diverse patient populations.
慢性乙肝病毒(HBV)感染对艾滋病毒感染者的影响尤为严重,而艾滋病毒感染者往往被排除在功能性治愈研究之外。本研究调查了HBV单一感染与HBV/艾滋病毒合并感染中的CD8 T细胞谱,研究长期治疗对病毒特异性反应的影响,旨在为免疫恢复的治疗策略提供依据。
我们分析了61名接受抑制性抗病毒治疗的参与者(HBV感染者20名、HBV/艾滋病毒合并感染者20名、艾滋病毒感染者21名)的CD8 T细胞反应。我们评估了转录组和蛋白质组谱,重点关注耗竭标志物以及病毒特异性功能能力。
转录组分析揭示了合并感染中的独特特征,与TCR信号传导、抑制途径和祖细胞耗竭标志物相关的基因上调。该基因谱在前体耗竭(Tpex)CD8+ T细胞特征方面得分很高,反映了一种“干性”程序,尽管长期暴露于抗原,但仍能保持可塑性。蛋白质组分析证实,合并感染中前体耗竭的TCF-1+CD127+PD-1-CD8 T细胞频率更高,而HBV单一感染中终末耗竭的Tox+TCF-1+CD127-细胞占主导。这些差异与合并感染中针对表面和核心抗原的更强有力、多功能的HBV特异性反应相关。合并感染中较低的HBsAg水平和较长的治疗持续时间与Tpex群体和功能反应呈正相关,与终末耗竭呈负相关。
我们的研究结果表明,HBV/艾滋病毒合并感染得到良好控制的个体维持更强大的CD8 T细胞反应,并保留支持持续抗病毒功能的干细胞样特性。这些结果强调了早期抗逆转录病毒干预的益处,以及需要定制免疫调节疗法来恢复这些不同患者群体的抗病毒功能。